Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Canaccord Genuity
John Newman Ph.D.
Cowen
Eric Schmidt Ph.D.
Credit Suisse
Alethia Young
Goldman Sachs
Terence Flynn Ph.D.
JP Morgan
Anupam Rama
Leerink Swann & Company
Michael Schmidt Ph.D.
Needham & Company
Chad Messer Ph.D.
Oppenheimer & Co.
Leah Rush Cann
RBC Capital Markets
Kennen MacKay Ph.D.
SunTrust Robinson Humphrey
Yatin Suneja

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.